FY2027 Earnings Estimate for ELVN Issued By HC Wainwright

Key Points

• HC Wainwright forecasts FY2027 EPS of ($2.06) for Enliven Therapeutics and maintains a Buy rating with a $73 price target, versus the current full-year consensus estimate of ($1.81).
• Enliven reported quarterly EPS of ($0.49), missing analysts’ consensus estimate of ($0.39) by $0.10. Analysts maintain a Moderate Buy consensus rating with an average price target of $75.44.
• The stock opened at $38.70, while insiders have sold 183,831 shares worth approximately $10.8 million over the past 90 days; institutional investors own 95.08% of the company.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Analysts at HC Wainwright issued their FY2027 earnings estimates for Enliven Therapeutics in a research note issued to investors on Monday, October 19th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($2.06) per share for the year. HC Wainwright currently has a "Buy" rating and a $73.00 target price on the stock. The consensus estimate for Enliven Therapeutics' current full-year earnings is ($1.81) per share.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10).

ELVN has been the subject of a number of other reports. The Goldman Sachs Group lifted their target price on Enliven Therapeutics from $67.00 to $80.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Wall Street Zen downgraded Enliven Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Barclays began coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They set an "overweight" rating and a $78.00 price target on the stock. JonesTrading raised their price target on Enliven Therapeutics from $45.00 to $70.00 and gave the company a "buy" rating in a research note on Monday, June 29th. Finally, Guggenheim restated a "buy" rating on shares of Enliven Therapeutics in a report on Thursday, October 8th. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $75.44.

Enliven Therapeutics Stock Up 3.7%

ELVN opened at $38.70 on Tuesday. The stock's fifty day moving average is $51.60 and its two-hundred day moving average is $47.95. The company has a market capitalization of $2.84 billion, a P/E ratio of -23.17 and a beta of 0.24. Enliven Therapeutics has a 52 week low of $14.78 and a 52 week high of $62.32.

Insider Activity

In related news, Director J. Scott Garland sold 13,000 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $46.67, for a total transaction of $606,710.00. Following the transaction, the director directly owned 13,000 shares of the company's stock, valued at $606,710. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $50.35, for a total transaction of $303,006.30. Following the transaction, the chief financial officer directly owned 38,000 shares in the company, valued at approximately $1,913,300. The trade was a 13.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 183,831 shares of company stock worth $10,823,298. Corporate insiders own 3.00% of the company's stock.

Institutional Trading of Enliven Therapeutics

Hedge funds have recently bought and sold shares of the stock. KBC Group NV acquired a new position in Enliven Therapeutics during the 1st quarter valued at approximately $38,000. State of Wyoming purchased a new position in shares of Enliven Therapeutics in the second quarter worth $96,000. FNY Investment Advisers LLC acquired a new stake in shares of Enliven Therapeutics during the second quarter worth $126,000. Arizona State Retirement System lifted its stake in shares of Enliven Therapeutics by 45.1% during the second quarter. Arizona State Retirement System now owns 13,007 shares of the company's stock worth $660,000 after buying an additional 4,042 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Enliven Therapeutics by 21.2% during the first quarter. The Manufacturers Life Insurance Company now owns 23,441 shares of the company's stock worth $919,000 after buying an additional 4,105 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven's pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.